CEO Today USA Awards

CONNECTICUT 43 www.ceotodaymagazine.com CEO Today USAAwards 2017 www.aptuit.com | www.evotec.com simplifying our services into 3 core business areas. We did had have to change culture to execute this strategy. Despite our EU based operations, we were able to create a global sales team to grow our US sales to 60% of global in 3 years whilst adding large pharma customers, and adding brand new accounts in Israel, Japan and Eastern Europe. Unusually for a service organization we had many joint press releases with customers Aptuit, an Evotec company, is a pharmaceutical services company that provides the most complete set of integrated early discovery to mid-phase drug development solutions by applying scientific excellence, outstanding service and a team of some of the foremost scientific professionals in the industry. Our broad range of integrated capabilities includes Drug Design & Discovery, API Development and Manufacture, Solid State Chemistry, Chemistry, Manufacturing and Controls, and Preclinical and IND enabling GLP/GMP programs. Fully integrated services are available fromour state-of-the- art facilities whereexperienced scientists inmultidisciplinary areas support pharmaceutical and biotech companies of every size and on a global scale. Aptuit’s offerings also include INDiGO®, a program to accelerate early drug candidates into the clinic by reducing time from candidate nomination to regulatory submission In August 2017, Aptuit was acquired by Evotec, a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. Evotec operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target- to-clinic to meet the industry’s need for innovation and efficiency in drug discovery (EVT Execute). Evotec has built a pipeline of more than 70 partnered product opportunities at clinical, pre-clinical and discovery stages, and has established multiple long-term discovery alliances with partners including Bayer, CHDI, Sanofi UCB and development partnerships with e.g. with Sanofi in the field of diabetes, with Pfizer in the field of tissue fibrosis and Celgene in the field of neurodegenerative diseases. Our new combined company now has more than 1600 outstanding scientists and experienced project management teams. We have expertise in a wide range of therapeutic areas including pain, oncology, metabolics, CNS, immunology, infection, fibrosis, respiratory, and cardiovascular. FIRM PROFILE